Annual Surveillance Mammography Decreasing in Breast Cancer Survivors
Rates of surveillance mammography were stable from 2004 to 2009 but declined 1.5% annually from 2009 to 2016.
Rates of surveillance mammography were stable from 2004 to 2009 but declined 1.5% annually from 2009 to 2016.
Immune checkpoint inhibitors were more effective than taxanes in patients with a high tumor mutational burden.
The risk of breakthrough SARS-CoV-2 infections was highest for liver cancer and lowest for thyroid cancer.
The incidence of pancreatic neuroendocrine tumors is increasing in the United States, but overall survival for these patients is improving.
Patients who did not receive EGFR TKIs had a significantly higher risk of dying or needing subsequent treatment.
Late relapse of triple-negative breast cancer is associated with biological factors but not sociodemographic factors, a study suggests.
Patients with CLL were significantly more likely to have an antibody response to the Moderna vaccine than to the Pfizer-BioNTech vaccine.
Patients in the very high risk group had a significantly higher risk of recurrence, metastasis, and death.
Although mortality-to-incidence indices are improving globally, the increasing burden of AML is “concerning,” according to researchers.
Recurrence rates were highest among patients who received at least 70% of treatments before noon.